ArticleEndocrine2026
Therapeutic central lymph node dissection in papillary thyroid cancer: what is the optimal extent in unilateral nodal disease?
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal extent of central lymph node dissection (CLND) in patients with unilateral papillary thyroid cancer (PTC) and clinical nodal involvement (cN1a) confined to the ipsilateral central compartment remains controversial due to its potential risks, including permanent hypoparathyroidism and recurrent laryngeal nerve palsy. This study aimed to assess the prevalence of contralateral central neck recurrence following omission of contralateral prophylactic CLND.
methodsA retrospective, single-center study was conducted, including patients with unilateral cN1a PTC who underwent ipsilateral CLND between 2010 and 2021. Exclusion criteria were: age < 18 years, prior neck surgery, non-papillary histologies, isthmus or pyramidal lobe tumors, T4b/M1 classification (AJCC 8th Ed.), R1-R2 resection status, bilateral multifocal disease, and nodal involvement limited to prelaryngeal and/or pretracheal chains.
resultsSeventy-five patients met the inclusion criteria, with a median follow-up of 61.6 (IQR: 34.95–85.18) months. Despite the presence of high-risk factors previously described for contralateral occult lymph node metastasis, including male sex, younger age, tumor size > 1 cm, aggressive histology, multifocal disease, lymphovascular invasion, > 5 metastatic central lymph nodes, and concomitant lateral neck nodal disease (cN1b), only 2/75 patients (2.7%) developed relapse. The 5- and 10-year contralateral central neck recurrence-free probabilities were both 97.2% (95% CI: 89.3–99.3%). Postoperative complications included transient hypocalcemia (12/75), permanent hypoparathyroidism (3/75), and recurrent laryngeal nerve injury, both transient (3/75) and permanent (1/75).
conclusionsOur findings suggest that restricting central neck dissection to the clinically affected side may be oncologically safe, minimizing complications associated with bilateral procedures.
Indexed as
Identifiers
42067700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.